日本厚生省自1996年以来收到与克拉霉素(clarithromycin)有关的肝功能障碍23例,横纹肌溶解6例报告。为此,对儿科用克拉霉素产品“Clarith”和“Klaricid”的标签进行修改,将肝功能障碍、黄疸和横纹肌溶解置于“临床重要不良反 Japan’s Ministry of Health and Welfare has received 23 cases of liver dysfunction associated with clarithromycin since 1996, and rhabdomyolysis has been reported in 6 cases. To this end, the pediatric clarithromycin products “Clarith” and “Klaricid” were modified to place liver dysfunction, jaundice and rhabdomyolysis in the "clinically important adverse reactions